Top Stories
As part of the conditional marketing authorisation, the MHRA will review new information on the GLP-1 drug at least every year.
Having only just moved its most advanced pipeline candidate into clinical trials, Scribe Therapeutics' IPO will test investor appetite for earlier-stage biotechs.
Junshi out-licensed certain rights for autoimmune candidate roconkibart to a subsidiary of Fosun, while Arcturus inked a manufacturing deal with Thermo Fisher for its inhaled cystic fibrosis therapy.
Early this quarter, the biotech will launch a pivotal trial evaluating its idopathic pulmonary fibrosis candidate against Roche's Esbriet.
The new collaboration will utilise CSPC's siRNA drug discovery platform and extrahepatic targeted delivery platform to develop small nucleic acid drug candidates for renal diseases across multiple indications.
Conference News
Munich, Germany – A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery, according to research pr...
Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer3 Jul 2026The phase III KRYSTAL-10 trial did not meet its co-primary survival endpointsThe ch...
Treatment duration of immunotherapy combination does not impact on disease-free survival in dMMR colon cancer3 Jul 2026An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the ...
It was a week of top-line tests across non–small-cell lung cancer, ulcerative colitis and mantle cell lymphoma, while Medicare’s GLP-1 bridge unfurled and Ipsen doubled up on 'niche-buster' dealmaking.
Date: 02 Jul 2026Munich, Germany –An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with...
